Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

DI MARCO, Vito
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.048
EU - Europa 11.235
AS - Asia 10.176
SA - Sud America 1.389
AF - Africa 268
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 16
Totale 47.169
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.659
SG - Singapore 3.862
RU - Federazione Russa 3.026
CN - Cina 2.415
IT - Italia 2.351
FI - Finlandia 1.390
BR - Brasile 1.098
HK - Hong Kong 993
VN - Vietnam 898
DE - Germania 875
UA - Ucraina 794
PL - Polonia 612
BD - Bangladesh 516
GB - Regno Unito 499
FR - Francia 456
IE - Irlanda 443
JP - Giappone 333
IN - India 264
SE - Svezia 218
KR - Corea 197
CA - Canada 188
TR - Turchia 123
IQ - Iraq 104
RO - Romania 100
AR - Argentina 99
MX - Messico 90
NL - Olanda 89
BE - Belgio 80
AT - Austria 76
ZA - Sudafrica 59
UZ - Uzbekistan 57
ES - Italia 51
CI - Costa d'Avorio 48
IR - Iran 44
PK - Pakistan 44
CO - Colombia 43
SA - Arabia Saudita 39
CZ - Repubblica Ceca 37
ID - Indonesia 36
EC - Ecuador 35
KE - Kenya 33
AU - Australia 31
MA - Marocco 31
PH - Filippine 31
VE - Venezuela 31
MY - Malesia 27
GR - Grecia 26
NP - Nepal 26
EG - Egitto 25
JO - Giordania 25
PY - Paraguay 25
JM - Giamaica 24
CL - Cile 22
AE - Emirati Arabi Uniti 20
TN - Tunisia 18
LT - Lituania 17
AZ - Azerbaigian 16
CH - Svizzera 16
DZ - Algeria 15
HN - Honduras 15
TH - Thailandia 15
LB - Libano 14
BG - Bulgaria 12
BO - Bolivia 12
CR - Costa Rica 11
GT - Guatemala 11
KG - Kirghizistan 11
UY - Uruguay 11
DK - Danimarca 10
OM - Oman 10
DO - Repubblica Dominicana 9
PA - Panama 9
AL - Albania 8
BY - Bielorussia 8
EU - Europa 8
GE - Georgia 8
IL - Israele 8
MM - Myanmar 8
NI - Nicaragua 8
PE - Perù 8
TT - Trinidad e Tobago 8
ET - Etiopia 7
KZ - Kazakistan 7
RS - Serbia 7
MD - Moldavia 6
NG - Nigeria 6
PT - Portogallo 6
SN - Senegal 6
BA - Bosnia-Erzegovina 5
GA - Gabon 5
GY - Guiana 5
SV - El Salvador 5
TW - Taiwan 5
XK - ???statistics.table.value.countryCode.XK??? 5
BN - Brunei Darussalam 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
CU - Cuba 3
FJ - Figi 3
NZ - Nuova Zelanda 3
Totale 47.118
Salva come PNG Salva come JPEG
Città #
Ashburn 2.872
Fairfield 2.834
Singapore 2.727
Woodbridge 1.437
San Jose 1.320
Chandler 1.311
Houston 1.168
Wilmington 1.139
Seattle 1.094
Cambridge 993
Hong Kong 946
Ann Arbor 867
Palermo 562
Zgierz 523
Moscow 502
Dublin 439
Jacksonville 418
Los Angeles 400
Beijing 397
Medford 397
Des Moines 349
Santa Clara 335
New York 327
Ho Chi Minh City 320
Tokyo 315
Helsinki 292
Altamura 285
Council Bluffs 276
Nanjing 268
Frankfurt am Main 261
Princeton 252
Lauterbourg 239
Hanoi 235
Lawrence 213
Dallas 207
Boardman 204
Chicago 200
San Diego 183
Buffalo 147
Hefei 143
The Dalles 135
Tulsa 110
Milan 103
Shenyang 99
São Paulo 98
Rome 84
Dearborn 82
Jinan 75
London 75
Phoenix 75
Brussels 72
Orem 72
Nanchang 70
Tianjin 69
Changsha 67
Nuremberg 66
Warsaw 64
Jiaxing 60
Ludwigshafen am Rhein 60
Hebei 59
Izmir 59
Atlanta 58
Columbus 55
Chennai 52
Salt Lake City 50
Zhengzhou 50
Abidjan 48
Falls Church 45
Denver 44
Guangzhou 43
Tampa 43
Tashkent 43
Montreal 41
Saint Petersburg 41
Baghdad 40
Kumar 40
Amsterdam 39
Haiphong 39
San Paolo di Civitate 39
Brooklyn 38
Da Nang 38
Ningbo 36
Seongnam 36
Elk Grove Village 35
Munich 34
Stockholm 33
Johannesburg 32
Mumbai 32
Verona 32
Nairobi 31
Ottawa 29
Rio de Janeiro 29
Hangzhou 28
Seoul 28
Shanghai 27
Redwood City 26
Vienna 26
Boston 25
San Francisco 25
Bremen 24
Totale 30.505
Salva come PNG Salva come JPEG
Nome #
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases 518
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 396
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 345
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 329
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 329
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 324
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 311
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 311
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 309
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 303
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 297
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 296
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 293
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. 284
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 282
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 281
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 280
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 273
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 272
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 266
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 263
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 261
Targeted Therapies in Hepatocellular Carcinoma 260
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. 258
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 257
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 255
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 255
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 251
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 249
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 249
Breaking bad news: How to cope 249
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 248
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 248
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 246
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 244
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 242
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 241
Adefovir for lamivudine resistant HBV: More than meets the eye. 240
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 240
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 238
La termoablazione nel trattamento delle neoplasie epatiche primitive e secondarie 237
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 237
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 233
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 233
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 232
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 232
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 230
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 230
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 230
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 229
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 229
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 229
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 228
A patient with acute hepatitis C and possible IFN toxicity [2] 227
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy 226
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. 224
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 223
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 223
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 221
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 221
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 221
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 219
Oral Mucosa of celiac disease patients produces anti-endomysial and anti-transglutaminase antibodes. Diagnostic usefulness of an in vitro culture system 217
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 217
Halitosis: could it be more than mere bad breath? 217
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 217
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 216
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 215
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 214
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 212
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 211
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 211
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 209
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 208
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 208
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 207
Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. 202
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 201
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 200
Sorafenib: from literature to clinical practice 199
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 199
HCV clearance among hemophiliacs and beta-thalassemics 198
AISF position paper on HCV in immunocompromised patients 198
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 198
Liver stiffness quantification in patients with non-alcoholic steatohepatitis: comparison of shear wave elastography and transient elastography with liver biopsy correlation 198
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 197
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 197
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 197
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 197
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 196
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 196
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 196
Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials 194
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 194
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 193
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 193
Metformina e pioglitazone in soggetti affetti da diabete mellito tipo 2 con steatosi epatica 193
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 193
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. 192
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center 192
Totale 23.999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.080 137 659 128 94 107 134 172 165 379 371 224 510
2022/20233.944 390 835 51 419 413 625 274 264 426 17 155 75
2023/20241.552 76 244 106 116 132 388 144 85 22 37 12 190
2024/20254.837 106 290 217 424 155 185 297 258 369 898 604 1.034
2025/202618.185 1.145 490 909 1.369 1.710 2.773 2.329 1.901 1.373 2.282 915 989
2026/2027425 425 0 0 0 0 0 0 0 0 0 0 0
Totale 48.361